Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Deals

Sihuan Pharma to Sell Generic Drug Businesses, Shift Focus to Aesthetics and Biologics

Fineline Cube Jul 18, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced plans to divest a portion of...

Company Drug

Luye Pharma’s Lurbinectedin Receives Hainan Approval for SCLC Treatment

Fineline Cube Jul 18, 2022

China-based Luye Pharma Group (HKG: 2186) announced approval from the Hainan Medical Products Administration for...

Company Drug

Novartis’ Aimovig Launches in China via GBA Early Access Scheme for Migraine Treatment

Fineline Cube Jul 15, 2022

Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first...

Drug

CStone Pharmaceuticals’ Gavreto Wins Hong Kong Approval for RET Fusion NSCLC

Fineline Cube Jul 15, 2022

CStone Pharmaceuticals (HKG: 2616) announced that its RET inhibitor Gavreto (pralsetinib) has received marketing approval...

Company Medical Device

NMPA Approves RocketHeart’s LV Assist System and Our United Group’s Radiation Therapy Device

Fineline Cube Jul 15, 2022

The National Medical Products Administration (NMPA) has approved marketing for two innovative medical devices: RocketHeart’s...

Company Deals Digital

Ping An Good Doctor Partners with China Biotech Services for Cancer Testing and BNCT Treatment

Fineline Cube Jul 15, 2022

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company Drug

Kelun Pharma’s SKB264 ADC Receives NMPA Green Light for Phase II Solid Tumor Study

Fineline Cube Jul 15, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that its antibody drug conjugate (ADC)...

Company Drug

Luye Pharma Initiates Phase III Study of Trulicity Biosimilar BA5101 in China

Fineline Cube Jul 15, 2022

China-based Luye Pharma Group (HKG: 2186) announced the initiation of a Phase III clinical study...

Company Deals

Shanghai Electric and Siemens Partner on Localization of High-End Medical Equipment

Fineline Cube Jul 15, 2022

China’s Shanghai Electric Group has partnered with Germany-based Siemens Healthineers to localize high-end medical equipment,...

Company Drug

Beijing Science Sun’s LZ901 Shingles Vaccine Receives FDA IND Approval

Fineline Cube Jul 15, 2022

China-based Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced that its subsidiary Beijing Luzhu...

Company Deals

Ningbo HicRen Biotech Completes RMB100M Pre-Series C Financing for Orthopedic Robots

Fineline Cube Jul 15, 2022

Ningbo HicRen Biotechnology Co., Ltd, a China-based robotics-driven minimally invasive orthopedics platform, announced the completion...

Company Deals

CStone Pharmaceuticals Explores Strategic Options Including Buyout

Fineline Cube Jul 15, 2022

China-based CStone Pharmaceuticals (HKG: 2616) is evaluating strategic options, including a potential buyout, according to...

Drug

BeiGene’s Tislelizumab Faces FDA Delay Due to Inspection Hurdles

Fineline Cube Jul 15, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced a delay in the U.S. FDA’s decision...

Company Deals Drug

Frontier Biotech and Asymchem Partner on COVID-19 Drug FB2001 Development

Fineline Cube Jul 15, 2022

China-based Frontier Biotechnologies Inc. (SHE: 200342) announced a strategic partnership with Asymchem Laboratories (Tianjin) Co.,...

Company Medical Device

Acotec Scientific’s AcoArt Orchid & Dhalia DCB Wins China Approval for AVF PTA

Fineline Cube Jul 14, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that its AcoArt Orchid & Dhalia DCB,...

Company Deals

Orion Holdings to Build Jining Vaccine Plant in China’s Shandong Province

Fineline Cube Jul 14, 2022

South Korea-based conglomerate Orion Holdings Corp. will enter China’s vaccine market by constructing a manufacturing...

Company Drug

Hangzhou DAC Biotech Doses First Patient in DXC007 AML Study

Fineline Cube Jul 14, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing in a...

Company Deals

Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline

Fineline Cube Jul 14, 2022

China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its...

Company Drug

Simcere’s Trilaciclib Wins NMPA Approval for Chemotherapy Myeloprotection

Fineline Cube Jul 14, 2022

Jiangsu Simcere Pharmaceutical Co., Ltd’s trilaciclib has received marketing approval from the National Medical Products...

Policy / Regulatory

China’s 2021 Healthcare Report Shows Rising Life Expectancy, Increased Medical Spending

Fineline Cube Jul 14, 2022

China’s National Health Commission (NHC) released the “Healthcare Statistical Communique 2021,” revealing increased healthcare spending,...

Posts pagination

1 … 649 650 651 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.